Press Release

To, Date: 1st November, 2026 The Manager The Manager, BSE Limited NSE Limited, P. J. Towers, Dalal Street Exchange Plaza, Bandra Kurla Complex, Mumbai-400001 Bandra (E), Mumbai- 400051. (BSE Scrip Code: 544742) (NSE Symbol: SAIPARENT) Dear Sir/Madam, Unit: Sai Parenterals Limited Subject: Investors Press Release on the Standalone & Consolidated Un-audited financial results for the quarter ended 30th September, 2026 Pursuant to Regulation 30(6) of the SEBI (LODR) Regulations 2015, please find the enclosed herewith the Press Release on the Standalone & Consolidated Un-audited financial results for the quarter ended 30th September, 2026. The Investor Press Release may also be accessed on the website of the Company at https://www.saiparenterals.com/ Request you to kindly take the same on record. Thanking you, Yours faithfully, For Sai Parenterals Limited Mr. Anil Kumar Karusala Managing Director (DIN- 01866646) Encl: As above Investor Release Sai Parenterals Limited Q2 & H1 FY27 Financial & Business Highlights Hyderabad, 01st November 2026 – Sai Parenterals Limited, is an integrated, IP-led pharmaceutical enterprise operating across two complementary verticals — contract development and manufacturing for international customers, and branded generic formulations sold domestically and exported into regulated and semi-regulated markets. It has announced its un-audited Financial Results for the quarter and half- year ended 30th September 2026. Financial Highlights – Q2FY27 (Consolidated) Revenue from Gross Profit EBITDA PAT Operations Rs. 93 crores Rs. 41 crores Rs. 11 crores Rs. 196 crores Margin 47.5% Margin 21.1% Margin 5.4% Financial Highlights – H1FY27 (Consolidated) Revenue from Gross Profit EBITDA PAT Operations Rs. 167 crores Rs. 66 crores Rs. 18 crores Rs. 376 crores Margin 44.3% Margin 17.6% Margin 4.9% Key Consolidated Financial Highlights Particulars (in Rs. Crs.) Q2 FY27 Q2 FY26 Q1 FY27 QoQ H1 FY27 H1 FY26 Revenue From Operations 196.1 54.9 179.9 9.0% 376.0 89.3 Gross Profit 93.1 20.1 73.7 26.4% 166.7 32.7 Gross Profit Margin (%) 47.5% 36.7% 40.9% 44.3% 36.6% EBITDA 41.4 12.8 24.7 67.4% 66.1 18.6 EBITDA Margin (%) 21.1% 23.3% 13.7% 17.6% 20.8% PAT 10.5 7.2 7.9 32.7% 18.4 7.8 PAT Margin (%) 5.4% 13.1% 4.4% 4.9% 8.7% Note: Consolidated figures for Q2 & H1 FY27 include a full quarter of Noumed Pharmaceuticals; Q2 & H1 FY26 does not, Noumed having been consolidated with effect from November 12, 2025. Year-on-year comparison is accordingly not like-for-like. • Revenue from operations stood at Rs. 196.1 crore, up 9.0% q-o-q from Rs. 179.9 crore in Q1FY27. H1FY27 revenue of Rs. 376.0 crore represents approximately 50% of the FY27 revenue target of Rs. 750 crore, ahead of the guided 45:55 phasing between the two halves. • Gross profit stood at Rs. 93.1 crore, up 26.4% q-o-q, with gross margin rising to 47.5% from 40.9% in Q1FY27. The improvement reflects tighter inventory management: higher-cost inventory from earlier periods was consumed, and first-in, first-out controls were introduced on a new ERP system. Investor Release • EBITDA stood at Rs. 41.4 crore, up 67.4% q-o-q, with EBITDA margin at 21.1% against 13.7% in Q1FY27. H1FY27 EBITDA margin stood at 17.6%, ahead of the ~17% guided for FY27. • Depreciation and amortisation rose to Rs. 25.1 crore from Rs. 8.1 crore in Q1FY27. The increase reflects the capitalisation of the Unit III expansion and of Noumed assets, the consolidation of Saicriti Pharma, and amortisation of molecules acquired from Sai Prathyak Laboratories. • Despite a more than threefold sequential rise in depreciation, PAT grew 32.7% q-o-q to Rs. 10.5 crore in Q2FY27. H1FY27 PAT stood at Rs. 18.4 crore. Key Business and Strategic Developments IPO proceeds deployed: both acquisitions completed • Following shareholders’ approval of the variation in the objects of the issue, the Company has completed the acquisition of 60% stakes in Saicriti Pharma Private Limited and Prathyak Laboratories Private Limited. It invested Rs. 98.8 crore of IPO proceeds: Rs. 83.83 crore in Saicriti and Rs. 15 crore in Prathyak. The balance of Rs. 3.0 crore, from the amount originally earmarked for a research centre, has been reallocated to general corporate purposes. • The purpose for which the IPO funds were raised remains unchanged: EU-GMP compliant injectable capacity for regulated markets, and a dedicated research and development platform. Only the manner of execution has been varied. Saicriti Pharma: new critical-care injectable facility on track for July 2027 • Foundation works are under way at the Gummadidala site, outside the Outer Ring Road, and construction will accelerate following the Company’s equity infusion. The facility is targeted for completion in July 2027. • Layout design is complete. Purchase orders have been placed for all four process lines: • liquid and lyophilised injectables • pre-filled syringe and cartridge combi-filling for GLP-1 products • dry powder filling • ampoule filling • Clean utilities and HVAC systems are in detailed engineering. • On completion, the facility will take injectable capacity to approximately 154.66 million units, built to EU-GMP and USFDA standards. Units I and II at Jeedimetla will be discontinued once it is commissioned. Sai Prathyak Laboratories: Group R&D consolidated • The acquisition of a 60% stake in Prathyak Laboratories was completed on 5th October 2026 for Rs. 15 crore. The company is now a direct subsidiary, renamed Sai Prathyak Laboratories Private Limited. Investor Release Key Business and Strategic Developments • The Genome Valley centre brings 28 research scientists and a portfolio of 174 molecules and 285 SKUs across critical care and oncology. Pre-acquisition molecules remain with the seller. The Group may use them for its own manufacturing and Saicriti is entitled to transfer them to its upcoming site. • All Group R&D has been consolidated at Sai Prathyak, which will begin taking external CDMO development contracts over the next two quarters, with revenue from FY28. The residual 40% may be acquired through a right of first refusal at the same valuation. Unit III expansion completed • The expansion at Unit III, Bhongir, is complete, raising production capacity by 81%, from 85.5 to 155 million units a month. It adds: • a high-capacity ointment manufacturing tank with an automated tube-filling line • a dedicated capsule blending suite with high-speed capsule filling • new liquid oral manufacturing and filling lines • Output ramps up from Q4FY27, with most of the additional volume serving Australia and New Zealand. Noumed: contracted Australian OTC supply rises to AUD 232 million • On 25th August 2026, Noumed renewed its OTC medicines supply agreement with one of Australia’s leading pharmacy chains. The three-year renewal is valued at AUD 30 million (approximately Rs. 204 crore). Together with the 7.5-year, AUD 202 million agreement renewed on 1 July 2026, contracted Australian OTC supply now stands at AUD 232 million (approximately Rs. 1,506 crore). • Both agreements provide for new products and line extensions over their terms. Volumes are largely sourced from third-party manufacturers today. As the Adelaide facility commissions and Indian capacity expands, production will progressively move in-house, converting a distribution margin into a manufacturing margin. Adelaide facility • The Adelaide facility will begin operations in January 2027, with commercial supply expected from around April 2027. Until then, the Company will support Noumed with bulk tablets from India. Philippines: portfolio expansion • 11 molecules and 22 SKUs were added or launched in the Philippines during Q2FY27, led by cardiovascular therapies including telmisartan–amlodipine, sacubitril– valsartan and rosuvastatin. Investor Release Commenting on the Result, Mr. Anil Kumar Karusala , Chairman and Managing Director, Sai Parenterals Limited said: Q2FY27 is the quarter in which our transformation began to show in our [Showing first 8,000 characters — download PDF for full document]